Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva To Divest Women's Health, Some Oncology As CEO Search Proceeds

Executive Summary

The company is pursuing the sale of global women's health and its oncology and pain businesses in Europe, Interim CEO Yitzhak Peterburg said during the firm's first quarter earnings call.

You may also be interested in...



Teva Offloads Women's Health Business To Two Firms For $1.38Bn

The generic drug maker signed two deals to divest its women's health business, one with the equity investment firm CVC Capital Partners and the other with Foundation Consumer Healthcare.

Teva Offloads Women's Health Business To Two Firms For $1.38Bn

The generic drug maker signed two deals to divest its women's health business, one with the equity investment firm CVC Capital Partners and the other with Foundation Consumer Healthcare.

Teva SOS: Troubled Drug Maker Seeks Audacious Captain To Take The Wheel

Teva investors have moved beyond restless to the point of jumping ship as the company's generic drug business continues to underperform, with little guidance on plans for a turnaround.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC098729

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel